The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes
Uložené v:
| Názov: | The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes |
|---|---|
| Autori: | Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Niels H. Brandt‐Jacobsen, Peter Gæde, Peter Rossing, Jens Faber, Silvio E. Inzucchi, Finn Gustafsson, Caroline Kistorp |
| Zdroj: | Jürgens, M, Schou, M, Hasbak, P, Kjær, A, Wolsk, E, Zerahn, B, Brandt-Jacobsen, N H, Gæde, P, Rossing, P, Faber, J, Inzucchi, S E, Gustafsson, F & Kistorp, C 2023, ' The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes ', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 2888-2896 . https://doi.org/10.1111/dom.15183 |
| Informácie o vydavateľovi: | Wiley, 2023. |
| Rok vydania: | 2023 |
| Predmety: | Cardiovascular Diseases/epidemiology, Benzhydryl Compounds/adverse effects, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, heart failure, SGLT2 inhibitor, Type 2/complications, GFR, 3. Good health, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetes Mellitus, Humans, type 2 diabetes, extracellular volume, Plasma Volume, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, plasma volume, Glomerular Filtration Rate |
| Popis: | AimsTo investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events.Materials and MethodsIn this prespecified substudy of the randomized, placebo‐controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between‐group change in mGFR, measured by the 51Cr‐EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included.ResultsFrom April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention‐to‐treat analysis. Treatment with empagliflozin reduced mGFR by −7.9 mL/min (95% confidence interval [CI] −11.1 to −4.7; P P = 0.003) and estimated PV by −128.9 mL (95% CI −218.0 to 39.8; P = 0.005) at Week 13.ConclusionsTreatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events. |
| Druh dokumentu: | Article |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/dom.15183 |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/37395341 https://curis.ku.dk/ws/files/365745929/Diabetes_Obesity_Metabolism_2023_J_rgens.pdf |
| Rights: | CC BY NC ND |
| Prístupové číslo: | edsair.doi.dedup.....65373f9f9c1daeb9ee5af982b3a2033f |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | AimsTo investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events.Materials and MethodsIn this prespecified substudy of the randomized, placebo‐controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between‐group change in mGFR, measured by the 51Cr‐EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included.ResultsFrom April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention‐to‐treat analysis. Treatment with empagliflozin reduced mGFR by −7.9 mL/min (95% confidence interval [CI] −11.1 to −4.7; P P = 0.003) and estimated PV by −128.9 mL (95% CI −218.0 to 39.8; P = 0.005) at Week 13.ConclusionsTreatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events. |
|---|---|
| ISSN: | 14631326 14628902 |
| DOI: | 10.1111/dom.15183 |